Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 20Carcinoma, Renal Cell 17Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 13Neoplasms 11Neuroendocrine Tumors 10Recurrence 8Lung Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Prostatic Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma 5Leukemia, Myeloid, Acute 5Kidney Neoplasms 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Hodgkin Disease 4Head and Neck Neoplasms 4Glioblastoma 4Waldenstrom Macroglobulinemia 3Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3

Interventions

Trastuzumab 2Oxaliplatin 2Leucovorin 2vatalanib 1tipifarnib 1temsirolimus 1pentetreotide 1napabucasin 1irinotecan sucrosofate 1Vinorelbine 1Taxes 1Sirolimus 1Paclitaxel 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1Gemcitabine 1Fluorouracil 1Floxuridine 1Everolimus 1Albumin-Bound Paclitaxel 190Y-octreotide, DOTA-Tyr(3)- 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Islet Cell × Everolimus × Clear all
NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Mayo Clinic

Phase 1 Completed
96 enrolled
DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡